Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial - PubMed (original) (raw)
Clinical Trial
. 2000 Jul 29;356(9227):385-90.
doi: 10.1016/S0140-6736(00)02530-7.
Affiliations
- PMID: 10972371
- DOI: 10.1016/S0140-6736(00)02530-7
Clinical Trial
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
P J Mease et al. Lancet. 2000.
Abstract
Background: Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which tumour necrosis factor, a proinflammatory cytokine, is present in increased concentrations in joints and in the skin. Therefore, psoriatic arthritis and psoriasis may be appropriate therapeutic targets for etanercept.
Methods: This randomised, double-blind, placebo-controlled, 12 week study assessed the efficacy and safety of etanercept (25 mg twice-weekly subcutaneous injections) or placebo in 60 patients with psoriatic arthritis and psoriasis. Psoriatic arthritis endpoints included the proportion of patients who met the Psoriatic Arthritis Response Criteria (PsARC) and who met the American College of Rheumatology preliminary criteria for improvement (ACR20). Psoriasis endpoints included improvement in the psoriasis area and severity index (PASI) and improvement in prospectively-identified individual target lesions.
Findings: In this 12 week study, 26 (87%) of etanercept-treated patients met the PsARC, compared with seven (23%) of placebo-controlled patients. The ARC20 was achieved by 22 (73%) of etanercept-treated patients compared with four (13%) of placebo-treated patients. Of the 19 patients in each treatment group who could be assessed for psoriasis (> or = 3% body surface area), five (26%) of etanercept-treated patients achieved a 75% improvement in the PASI, compared with none of the placebo-treated patients (p=0.015). The median PASI improvement was 46% in etanercept-treated patients versus 9% in placebo-treated patients; similarly, median target lesion improvements were 50% and 0, respectively. Etanercept was well tolerated.
Interpretation: Etanercept offers patients with psoriatic arthritis and psoriasis a new therapeutic option for control of their disease.
Comment in
- Case definition of psoriatic arthritis.
Spadaro A, Riccieri V, Taccari E. Spadaro A, et al. Lancet. 2000 Dec 16;356(9247):2095-6; author reply 2096. doi: 10.1016/S0140-6736(05)74302-6. Lancet. 2000. PMID: 11145511 No abstract available. - Case definition of psoriatic arthritis.
Taylor WJ, Fellow DE, Helliwell PS. Taylor WJ, et al. Lancet. 2000 Dec 16;356(9247):2095; author reply 2096. doi: 10.1016/S0140-6736(00)03417-6. Lancet. 2000. PMID: 11145512 No abstract available. - Case definition of psoriatic arthritis.
Marzo-Ortega H, McGonagle D, Veale D, Emery P. Marzo-Ortega H, et al. Lancet. 2000 Dec 16;356(9247):2095; author reply 2096. doi: 10.1016/S0140-6736(05)74301-4. Lancet. 2000. PMID: 11145513 No abstract available.
Similar articles
- Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B. Sterry W, et al. BMJ. 2010 Feb 2;340:c147. doi: 10.1136/bmj.c147. BMJ. 2010. PMID: 20124563 Clinical Trial. - Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A, Esposito M, Costanzo A, Chimenti S. Mazzotta A, et al. Am J Clin Dermatol. 2009;10(5):319-24. doi: 10.2165/11310770-000000000-00000. Am J Clin Dermatol. 2009. PMID: 19658444 Clinical Trial. - Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
Culy CR, Keating GM. Culy CR, et al. Drugs. 2002;62(17):2493-537. doi: 10.2165/00003495-200262170-00013. Drugs. 2002. PMID: 12421111 Review. - Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept.
Mease P. Mease P. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S116-21. Clin Exp Rheumatol. 2002. PMID: 12463460 Review. - Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Dunn M, Tsuji W. Mease PJ, et al. J Rheumatol. 2006 Apr;33(4):712-21. Epub 2006 Feb 1. J Rheumatol. 2006. PMID: 16463435 Clinical Trial.
Cited by
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.
Martí-Carvajal AJ, Gemmato-Valecillos MA, Monge Martín D, Dayer M, Alegría-Barrero E, De Sanctis JB, Parise Vasco JM, Riera Lizardo RJ, Nicola S, Martí-Amarista CE, Correa-Pérez A. Martí-Carvajal AJ, et al. Cochrane Database Syst Rev. 2024 Sep 19;9(9):CD014741. doi: 10.1002/14651858.CD014741.pub2. Cochrane Database Syst Rev. 2024. PMID: 39297531 - Early psoriatic arthritis: when is the right time to start advanced therapy?
Hen O, Harrison SR, De Marco G, Marzo-Ortega H. Hen O, et al. Ther Adv Musculoskelet Dis. 2024 Jul 27;16:1759720X241266727. doi: 10.1177/1759720X241266727. eCollection 2024. Ther Adv Musculoskelet Dis. 2024. PMID: 39071239 Free PMC article. Review. - Cell death as an architect of adult skin stem cell niches.
Lecomte K, Toniolo A, Hoste E. Lecomte K, et al. Cell Death Differ. 2024 Aug;31(8):957-969. doi: 10.1038/s41418-024-01297-3. Epub 2024 Apr 22. Cell Death Differ. 2024. PMID: 38649745 Free PMC article. Review. - Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis.
Montezuma T, Probst LF, Almeida MO. Montezuma T, et al. Adv Rheumatol. 2024 Mar 21;64(1):21. doi: 10.1186/s42358-024-00361-3. Adv Rheumatol. 2024. PMID: 38515177 - Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis.
Haberman RH, Zhou YY, Catron S, Felipe A, Jano K, Reddy SM, Scher JU. Haberman RH, et al. J Rheumatol. 2024 Mar 1;51(3):318-320. doi: 10.3899/jrheum.2023-0909. J Rheumatol. 2024. PMID: 38428986 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous